CASE NAME: Alicia Shelly v. Proempire, LLC dba Vitamatic

CASE NO.: 8:26-cv-01632

JURISDICTION: United States District Court for the Central District of California

FILED ON: June 24, 2026

CLASS DEFINITION: The lawsuit seeks to represent a nationwide class of consumers who purchased the identified Vitamatic dietary supplements for personal or household use, as well as a California subclass of California purchasers.

SUMMARY:

A proposed class action alleges that Proempire, LLC, doing business as Vitamatic, misled consumers by prominently displaying dosage amounts on the front labels of several dietary supplements in a way that allegedly caused reasonable consumers to believe each individual gummy, capsule, or tablet contained the advertised amount. According to the complaint, consumers actually must take two or three units to obtain the stated dosage listed on the front of the packaging. The plaintiff alleges this labeling practice caused consumers to overpay because they believed they were receiving more active ingredients per unit than they actually received. The lawsuit seeks damages, restitution, injunctive relief, corrective advertising, and certification of a nationwide class and California subclass.

ALLEGATIONS:

Vitamatic markets and sells several dietary supplements with dosage claims prominently displayed on the front of the packaging, including:

• Vitamatic Fiber 7g Gummies
• Vitamatic Black Garlic 1000 mg
• Vitamatic Magnesium Lysinate Glycinate 2000 mg
• Vitamatic L-Carnitine 1000 mg
• Vitamatic NADH 20 mg
• Vitamatic Pancreatin 10x 200 mg

The lawsuit alleges that consumers reasonably interpret these front-label statements to mean each gummy, capsule, or tablet contains the advertised dosage. However, the complaint contends that the Supplement Facts panel reveals the listed dosage applies to a serving consisting of multiple units rather than a single gummy, capsule, or tablet.

For example, the complaint alleges consumers must take three Fiber 7g Gummies to receive seven grams of fiber, while two capsules or tablets are required to receive the advertised dosage for the remaining products. According to the plaintiff, this distinction is not made sufficiently clear on the front label, resulting in consumers believing they receive substantially more active ingredients per individual unit than they actually do.

The complaint further alleges that competing supplement manufacturers either accurately identify the dosage contained in each individual unit or clearly disclose on the front of the package that the advertised dosage is “per serving.” The plaintiff claims Vitamatic instead used front-label dosage statements without comparable clarification, allegedly creating a misleading impression regarding potency per gummy, capsule, or tablet.

Plaintiff Alicia Shelly alleges she purchased Vitamatic Fiber 7g Gummies in California in February 2026 after reviewing and relying upon the product’s front-label dosage representation. According to the complaint, she believed each gummy contained seven grams of fiber and would not have purchased the product, or would have paid less, had she known that three gummies were required to obtain that amount.

The lawsuit asserts that the alleged labeling practices enabled the company to charge premium prices while providing less active ingredient per individual unit than consumers expected. The plaintiff contends that reasonable consumers were economically injured because they allegedly received less value than represented on the front labels.

The complaint brings claims under California’s Unfair Competition Law, False Advertising Law, and Consumer Legal Remedies Act, along with claims for breach of express warranty, breach of implied warranty, negligent misrepresentation, intentional misrepresentation, and unjust enrichment.

As relief, the plaintiff requests certification of a nationwide class and California subclass, restitution, compensatory and punitive damages where permitted, attorneys’ fees and costs, corrective advertising, and an injunction requiring Vitamatic to stop using the challenged labeling practices and provide accurate dosage disclosures on its products.